
Anumigilimab
CAS No. 2416593-08-1
Anumigilimab( —— )
Catalog No. M36769 CAS No. 2416593-08-1
Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 375 | Get Quote |
![]() ![]() |
5MG | 586 | Get Quote |
![]() ![]() |
10MG | 834 | Get Quote |
![]() ![]() |
25MG | 1224 | Get Quote |
![]() ![]() |
50MG | 1647 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAnumigilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.
-
DescriptionAnumigilimab (CSL-324) is an humanized IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
Recptorc-Fms
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2416593-08-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Markota ?agalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23(7):3753. ?
molnova catalog



related products
-
Axatilimab
Axatilimab (SNDX-6352) is a human IgG4 antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), which can be used for the study of immune system disorders and respiratory diseases.
-
Gimsilumab
Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.
-
Mavrilimumab
Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.